Treatment Outcomes of Advanced Stage Classical Hodgkin Lymphoma in the Setting of Vinblastine and Dacarbazine Shortages: A Case Series
Case Reports in Oncological Medicine · 2026-01 · 2026 (1)
DOI: 10.1155/crom/5446464 ↗Kurz gefasst
Fachartikel in der Zeitschrift Case Reports in Oncological Medicine, online erschienen am 03.04.2026. Verfasst von Ishwarya Satyavarapu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Houston Methodist The Woodlands Hospital, Conroe, Texas, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Oncology drug shortages have significant implications on patient care, particularly with curative intent therapeutic strategies. This case series highlights strategic management for patients with classical Hodgkin lymphoma (cHL) in the setting of recent dacarbazine and vinblastine shortages without compromising outcomes. Summary cHL is a highly curable malignancy with initial treatment strategies incorporating chemotherapy, radiation therapy, chemoradiotherapy, or chemoimmunotherapy. The standard of care for patients with cHL includes a backbone of doxorubicin, vinblastine, and dacarbazine (AVD) based therapies in combination with either bleomycin, brentuximab vedotin (BV), or nivolumab. However, in 2023, critical shortages of dacarbazine and vinblastine led to rationing of these agents, raising concerns for a paucity of clear management strategies in patients with cHL. The three patients described in this case series received lower cumulative doses of standard chemotherapy as opposed to alternative therapies without compromising outcomes.
Conclusion
Treatment of advanced stage cHL during dacarbazine and vinblastine shortage requires careful consideration of alternative therapies and collaborative effort among healthcare professionals. This case series highlights that with a response‐added approach and vigilant monitoring, effective cancer treatment strategies may be implemented despite drug shortages.
Autor:innen und Institutionen
- Department of Medicine, Houston Methodist The Woodlands Hospital, Conroe, Texas, USA.
- Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA, houstonmethodist.org.
- The University of Texas Cancer Center, Houston, Texas, USA, mdanderson.org.
- Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, Texas, USA, houstonmethodist.org.
- Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA, houstonmethodist.org.
ORCID-Profile: Ishwarya Satyavarapu, Noah Giese, Godsfavour Umoru, Ethan A Burns, Sai Ravi Pingali
Zitieren
APA
Satyavarapu, I., Giese, N., Gandhi, P., Umoru, G., Burns, E. A., & Pingali, S. R. (2026). Treatment Outcomes of Advanced Stage Classical Hodgkin Lymphoma in the Setting of Vinblastine and Dacarbazine Shortages: A Case Series. Case Reports in Oncological Medicine, 2026(1). https://doi.org/10.1155/crom/5446464
Vancouver
Satyavarapu I, Giese N, Gandhi P, Umoru G, Burns EA, Pingali SR. Treatment Outcomes of Advanced Stage Classical Hodgkin Lymphoma in the Setting of Vinblastine and Dacarbazine Shortages: A Case Series. Case Reports in Oncological Medicine. 2026;2026(1). doi:10.1155/crom/5446464
BibTeX
@article{Satyavarapu2026,
author = {Satyavarapu, Ishwarya and Giese, Noah and Gandhi, Prakruti and Umoru, Godsfavour and Burns, Ethan A and Pingali, Sai Ravi},
title = {Treatment Outcomes of Advanced Stage Classical Hodgkin Lymphoma in the Setting of Vinblastine and Dacarbazine Shortages: A Case Series},
journal = {Case Reports in Oncological Medicine},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/crom/5446464}
}
EUVIMED